sartorious

German-based Sartorius has opened an €18m bioreactor production plant in Guxhagen, Hesse, Germany.

The new 100,000ft² facility will manufacture bioreactors and further production equipment for customers in the biopharmaceutical industry.

State government of Hesse prime minister, Volker Bouffier, said that by building a new production facility in the region, Sartorius has reinforced its close ties with northern Hesse.

"We offer companies an excellent infrastructure and intentionally promote the regional economy so that innovative medium-sized companies will invest in and stay with us," Bouffier said.

With the opening of the new building complex, which provides space for a high-tech manufacturing hall and offices for around 240 employees, the company has moved from its previous bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.

Sartorius has rented the premises in a long-term lease from Robos, the building owner.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sartorius CEO and executive board chairman Joachim Kreuzburg said the new plant enables the company to substantially enhance its manufacturing processes and creates additional capacity in view of the rising demand for biopharmaceutical production equipment.

"As a result, we are optimally prepared for further expansion, especially for single-use bioreactors," Kreuzburg said.


Image: Sartorius invested €18m in the expansion of manufacturing capacity. Photo: Courtesy of Sartorius.